PF-4708671

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

16 publications

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 107 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PF-4708671 has been cited by 16 publications

5 Customer Reviews

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

  • (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

  • Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

  • C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

  • Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 NUHmSFZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Wb2lEPTB;MD64NlAzPCEQvF2= M{HuPXNCVkeHUh?=
UACC-893 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DUbWlEPTB;NT6xPVg5PiEQvF2= M2XP[XNCVkeHUh?=
A427 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mzVWlEPTB;NT63NlU3PyEQvF2= M1L2bXNCVkeHUh?=
OCUB-M M13Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jDcGlEPTB;Nj62OlExOiEQvF2= M3Xrc3NCVkeHUh?=
SW684 M1Paemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPEXXc6UUN3ME23MlUzOjZ6IN88US=> NYX3WG5PW0GQR1XS
SK-LMS-1 M3nRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXtTWM2OD17LkCxN|AzKM7:TR?= Ml3xV2FPT0WU
CP50-MEL-B MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3hS3pKSzVyPUmuN|A1OTlizszN NV\TO|VnW0GQR1XS
NCI-H1651 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDSXnFlUUN3ME2xNE4xOjd4IN88US=> NYrhXFFQW0GQR1XS
ABC-1 NWjT[ZNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LJU2lEPTB;MUCuNVA{PyEQvF2= NHnFNWNUSU6JRWK=
OE19 NHLLR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFyLkG3N|Mh|ryP NGTlVGhUSU6JRWK=
DSH1 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3aO|dPUUN3ME2xNE45QDd7IN88US=> MVPTRW5ITVJ?
SW13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPJTWM2OD1zMT65N|E6KM7:TR?= NYXBTmE4W0GQR1XS
MDA-MB-453 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF{LkG2NFMh|ryP NFjPSHBUSU6JRWK=
647-V NVHIXGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqzR2xKSzVyPUGyMlM2QDJizszN M{S1VnNCVkeHUh?=
NCI-H2342 NH7meVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS4OIFKSzVyPUGyMlM6QTVizszN NETiZXdUSU6JRWK=
LB2241-RCC NWO4Nm45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfrVWtKSzVyPUGyMlU4PzlizszN M1XFZnNCVkeHUh?=
UACC-257 NUL3eFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHniUo1KSzVyPUGzMlQ1PTNizszN MXXTRW5ITVJ?
NCI-H661 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGyToxoUUN3ME2xN{43PDR7IN88US=> MkfKV2FPT0WU
FADU Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[yTWM2OD1zMz62PVkzKM7:TR?= NIDHTYxUSU6JRWK=
A2780 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q5UmlEPTB;MUOuPFA1OSEQvF2= MUHTRW5ITVJ?
NCI-H1793 NG[2UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX3VJVKSzVyPUG0MlQxQDVizszN NEnld2VUSU6JRWK=
TE-8 M1\sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPlTWM2OD1zNT6zOFY2KM7:TR?= M3nMRXNCVkeHUh?=
HGC-27 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfwb4M6UUN3ME2xOk4yPjR2IN88US=> NWrIVWZJW0GQR1XS
MMAC-SF MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjtTWM2OD1zNz6zO|I4KM7:TR?= M37kfnNCVkeHUh?=
Calu-6 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF6LkG1NVMh|ryP NWfLb3dnW0GQR1XS
HUTU-80 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF6LkO5OVkh|ryP MUPTRW5ITVJ?
SAS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH1TWM2OD1zOD62OFU2KM7:TR?= M{T2VXNCVkeHUh?=
IST-MES1 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\ve2lEPTB;MUiuOlUxQCEQvF2= Mo\XV2FPT0WU
C3A NFG0SmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni3TWM2OD1zOD63PVE6KM7:TR?= NFvIWGtUSU6JRWK=
ES3 NY\sdWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF6LkizOlQh|ryP NUTG[ocxW0GQR1XS
HSC-2 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vod2lEPTB;MUmuOlU1OSEQvF2= M{jyS3NCVkeHUh?=
T47D NX2xUohWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvBSHc{UUN3ME2yNE4yPDh3IN88US=> Mon4V2FPT0WU
EW-7 M1TVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jsUmlEPTB;MkCuPFU5QCEQvF2= MUDTRW5ITVJ?
LN-405 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJyLki5OlUh|ryP NF3PWGJUSU6JRWK=
U031 NXPkVYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJzLkS4NFIh|ryP Mlj6V2FPT0WU
A549 M1ricmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S3NGlEPTB;MkGuPFQ6OSEQvF2= MX;TRW5ITVJ?
RMG-I MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5[WlEPTB;MkKuNlY3QCEQvF2= MmnKV2FPT0WU
BT-474 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3jTWM2OD1{Mj62OVUyKM7:TR?= NWm4fYk{W0GQR1XS
NB69 NGfldpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHVTWM2OD1{Mz6xOVIh|ryP NUG2[WZiW0GQR1XS
NB7 MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HYVGlEPTB;MkSuNVg5KM7:TR?= M4TyXHNCVkeHUh?=
HCC1569 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rTWM2OD1{ND62NVI2KM7:TR?= MV3TRW5ITVJ?
MEL-JUSO M3rudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfqW|NKSzVyPUK0MlY6ODhizszN NHPZS5NUSU6JRWK=
MDA-MB-175-VII MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonITWM2OD1{NT6yOVE4KM7:TR?= MkTjV2FPT0WU
HCC1419 NX7nbpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rGRmlEPTB;MkWuOlAxOyEQvF2= MX3TRW5ITVJ?
Ca9-22 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPEWWhzUUN3ME2yOU43PDN{IN88US=> MojnV2FPT0WU
KGN NHXpOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XoZmlEPTB;MkWuO|U1PyEQvF2= M3GwN3NCVkeHUh?=
LB373-MEL-D NY\uTGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW1T4NKSzVyPUK2MlE6OzhizszN MkXnV2FPT0WU
NCI-H1755 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LiS2lEPTB;Mk[uPFg1OSEQvF2= M1qxR3NCVkeHUh?=
D-423MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ5LkC3NVUh|ryP MnL5V2FPT0WU
DK-MG NEXSPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PlTGlEPTB;MkiuO|g1PiEQvF2= NE\3UVRUSU6JRWK=
NCI-H1623 NWfPXHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnYcFZZUUN3ME2yPE45OzR{IN88US=> MlLJV2FPT0WU
KU-19-19 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELTcZJKSzVyPUK4Mlk6PSEQvF2= MnzNV2FPT0WU
C-33-A M2Dsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWzeI05UUN3ME2yPU4zOTl6IN88US=> NUfSfG9uW0GQR1XS
SCC-4 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNyLkOzOVQh|ryP MmPWV2FPT0WU
MG-63 MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNyLkW5PVQh|ryP NV3FfJk6W0GQR1XS
LNCaP-Clone-FGC NHTtcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTNzLkS5NlEh|ryP NIXEbGhUSU6JRWK=
CAPAN-1 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnyV5J3UUN3ME2zNU42Ojh4IN88US=> MVnTRW5ITVJ?
GI-ME-N NWO0PVAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvDZpJKSzVyPUOxMlU{PTNizszN NYfGU4JkW0GQR1XS
RERF-LC-MS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TJXWlEPTB;M{KuOlc1PyEQvF2= NHzIWYdUSU6JRWK=
KLE Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\2dGlEPTB;M{OuOFM{PCEQvF2= NUjkeHVsW0GQR1XS
KNS-81-FD M3XTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK4d49KSzVyPUOzMlUxODhizszN MkfHV2FPT0WU
DOK NV[zd4duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT5TWM2OD1|ND62OlEzKM7:TR?= NGTiVXdUSU6JRWK=
ACHN MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;NSGlEPTB;M{WuNVU5QCEQvF2= M1S3WnNCVkeHUh?=
KYSE-520 M1jKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN3LkKzOlEh|ryP NIPpR5JUSU6JRWK=
SBC-5 M1vlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN3LkWxNVYh|ryP NILyc2ZUSU6JRWK=
NCI-H28 NHnCWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfSXWhKSzVyPUO1MlY3QTVizszN MljQV2FPT0WU
ES7 NX2yVGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\4W2lEPTB;M{[uNlI1QSEQvF2= NI\3[oJUSU6JRWK=
A172 NXvt[nhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\TfodKSzVyPUO2MlQyQDdizszN NEjiN21USU6JRWK=
UM-UC-3 M{XG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnBTWM2OD1|Nz64O|Q3KM7:TR?= MofDV2FPT0WU
LXF-289 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPdZZKSzVyPUO4MlAxPDdizszN MmT1V2FPT0WU
KP-4 NInQNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTN6LkS3N|kh|ryP MX;TRW5ITVJ?
TE-1 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;0TWM2OD1|OT62OVg6KM7:TR?= M1HRN3NCVkeHUh?=
G-402 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRyLkC2NUDPxE1? M{PCc3NCVkeHUh?=
786-0 M3nzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[2OGlEPTB;NECuPVA6PiEQvF2= MkHyV2FPT0WU
K5 M{G3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTRzLkO2PFYh|ryP M1[3V3NCVkeHUh?=
SK-N-DZ MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTRzLkO4NlMh|ryP MVPTRW5ITVJ?
OVCAR-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n4PGlEPTB;NEGuO|U3QCEQvF2= NFzENlBUSU6JRWK=
T84 M4LYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f6PWlEPTB;NEKuNVI3OyEQvF2= Mn3vV2FPT0WU
GCIY MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzxPIpLUUN3ME20N{4xQDB|IN88US=> NUPseVNrW0GQR1XS
BB49-HNC NHW5bItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR|LkOzOFgh|ryP MnniV2FPT0WU
SNU-C2B NYXmNIhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGwTWM2OD12Mz62OFM3KM7:TR?= NFTVVWtUSU6JRWK=
TE-6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mxPWlEPTB;NEOuPFg6PCEQvF2= M1jkN3NCVkeHUh?=
23132-87 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTR2LkK5O|gh|ryP MXzTRW5ITVJ?
DMS-53 M3fsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTR2LkOzPFQh|ryP M17teXNCVkeHUh?=
ONS-76 NX:4b|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr1cJQ{UUN3ME20OE44PjZzIN88US=> NHi1eFVUSU6JRWK=
DMS-273 M2\MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHrTWM2OD12ND65OFMh|ryP M3vyO3NCVkeHUh?=
COLO-824 NXP2dIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrRXpZKSzVyPUS1Mlg4PzVizszN NXHRWFBYW0GQR1XS
DMS-114 NHiw[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nH[GlEPTB;NEWuPFkzPyEQvF2= NIWy[|BUSU6JRWK=
YKG-1 NUHIPFE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\MVXVtUUN3ME20Ok4xOzV3IN88US=> MmHHV2FPT0WU
RH-18 M4DKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR4LkO3N|Mh|ryP M2DR[3NCVkeHUh?=
NCI-H1355 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR4Lk[xPEDPxE1? NV22ZYFJW0GQR1XS
NCI-H2170 NEjIemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTR5Lke1PFQh|ryP M1fSWXNCVkeHUh?=
OC-314 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HUTmlEPTB;NEeuPFQ4QCEQvF2= NXS4[FhnW0GQR1XS
NCI-H2030 NU\tbpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorOTWM2OD12Nz64PVA3KM7:TR?= MkftV2FPT0WU
22RV1 NIqybIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H6OmlEPTB;NEeuPVAyPSEQvF2= NFHzOY5USU6JRWK=
G-401 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTITWM2OD12OD60OFE2KM7:TR?= MVzTRW5ITVJ?
YAPC Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrn[G5KSzVyPUS5MlgxPzNizszN NGjUc|RUSU6JRWK=
SW1573 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fZ[mlEPTB;NUCuNlQ{PSEQvF2= NX;Bb3RFW0GQR1XS
COLO-792 M2DzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrnNY1vUUN3ME21NE43OjN5IN88US=> M2nJfXNCVkeHUh?=
KNS-62 NFvOdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rLTWlEPTB;NUCuO|UxQCEQvF2= MlHUV2FPT0WU
NB5 M3vIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrMfmlPUUN3ME21NU41PTB7IN88US=> NF\HUXVUSU6JRWK=
CP66-MEL Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTVzLk[0NFgh|ryP MYDTRW5ITVJ?
CaR-1 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnQUpNKSzVyPUWyMlA3ODZizszN M363fHNCVkeHUh?=
CAL-54 NGntSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfBTWM2OD13Mj6xNVAzKM7:TR?= MoHlV2FPT0WU
8305C MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr0UphZUUN3ME21Nk4{OTVizszN MoT4V2FPT0WU
Calu-3 NV34e2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXZXXJxUUN3ME21Nk4{PzN|IN88US=> MWTTRW5ITVJ?
AU565 Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTV{LkW1NFkh|ryP MUXTRW5ITVJ?
CW-2 NYnFNpJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XJZ2lEPTB;NUKuPFY2PCEQvF2= NF:wbWRUSU6JRWK=
BEN NUDnSIZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\aUYM{UUN3ME21N{44QDZ{IN88US=> MXTTRW5ITVJ?
NCI-H1975 NI[yVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\Nd3VNUUN3ME21N{45QTZ4IN88US=> NXLHe45nW0GQR1XS
HCT-116 NV3TOYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7OWmNWUUN3ME21OE4xOzJ5IN88US=> MX7TRW5ITVJ?
SH-4 M2jEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DTZWlEPTB;NUSuNVM5KM7:TR?= NYjQNpp{W0GQR1XS
NCI-H1693 NHjaXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTV2LkKxNFMh|ryP MV7TRW5ITVJ?
BPH-1 NWnTSWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXkWlhKSzVyPUW1MlI5QTJizszN NVq4UJZGW0GQR1XS
CAMA-1 NVfqWoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXaSldiUUN3ME21OU45OTF4IN88US=> Ml3wV2FPT0WU
A388 NVHnSI1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTV4LkC5PFUh|ryP M4HtfHNCVkeHUh?=
C2BBe1 M4PsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTV4LkK2N|Qh|ryP NFmxZWpUSU6JRWK=
GAMG NX[1VWpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInJd2NKSzVyPUW2MlU6PTVizszN MlHXV2FPT0WU
MKN28 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTV4LkiwNVMh|ryP NYn1RmxQW0GQR1XS
VA-ES-BJ MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf0TWM2OD13Nj64O|Q2KM7:TR?= MY\TRW5ITVJ?
HuCCT1 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPFXIFKSzVyPUW3MlA1QTJizszN MWrTRW5ITVJ?
BFTC-905 NV;VWHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLlTWM2OD13Nz6yPFk5KM7:TR?= MnPRV2FPT0WU
LS-123 M4\WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTLTWM2OD13Nz61OlY5KM7:TR?= MVPTRW5ITVJ?
LB996-RCC NIf4TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnrR|loUUN3ME21PE4xOjh5IN88US=> NWrmfWZyW0GQR1XS
NCI-H1048 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PvOGlEPTB;NUiuNlE5QCEQvF2= M3raVXNCVkeHUh?=
COR-L105 NX;JVldGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTV6LkezN|ch|ryP M4DkcXNCVkeHUh?=
OVCAR-8 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjhTnZQUUN3ME21PU4yPzF4IN88US=> M{e5[XNCVkeHUh?=
SK-N-FI M{foWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTV7LkOyNFch|ryP NYXISnRjW0GQR1XS
MES-SA M{Lqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUexWWY{UUN3ME21PU41PTB7IN88US=> NIfBU3RUSU6JRWK=
SCC-9 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljWTWM2OD13OT60O|U{KM7:TR?= NUnMfop3W0GQR1XS
EFO-27 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX25OW9iUUN3ME21PU46PDNizszN MU\TRW5ITVJ?
GT3TKB NXu3TpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjrR2lKSzVyPU[wMlYxPDhizszN M2LZXXNCVkeHUh?=
HCC38 NHnjcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[3UHpKSzVyPU[xMlQ{PzlizszN NIrKcJJUSU6JRWK=
MLMA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHoTWM2OD14MT62NVY{KM7:TR?= MYXTRW5ITVJ?
D-566MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jpVGlEPTB;NkOuOVIzPCEQvF2= NG\tRlNUSU6JRWK=
SF295 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXwTHI{UUN3ME22N{43PjV3IN88US=> Mn\YV2FPT0WU
ES4 NVT0epJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrkeHVKSzVyPU[0MlQ4OTlizszN NHOwVHlUSU6JRWK=
CAKI-1 NEfyO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT1[pk{UUN3ME22OE42PzJzIN88US=> NUHVVGt1W0GQR1XS
OAW-28 M1\iVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TJdWlEPTB;NkSuPVY1PyEQvF2= NWfkc3VoW0GQR1XS
NCI-H460 M3ziZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLsR4dKSzVyPU[1MlA5QTdizszN MUHTRW5ITVJ?
JAR M{\vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzjTWM2OD14NT61OVE3KM7:TR?= NGf5[WFUSU6JRWK=
SNU-449 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlewTWM2OD14NT63OlE3KM7:TR?= MoHDV2FPT0WU
D-392MG M4Xk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTZ3Lkm0N|Qh|ryP Mm\JV2FPT0WU
EW-22 NVzGW|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr2ZmJKSzVyPU[2MlM6PSEQvF2= Mk\SV2FPT0WU
GCT NG[3XnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jmbGlEPTB;NkeuNFQ1OyEQvF2= M2TreXNCVkeHUh?=
NOS-1 NWfaOFdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2W|dyUUN3ME22O{43QDZ5IN88US=> MkPtV2FPT0WU
RH-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm1TWM2OD14OD61OVU6KM7:TR?= NFvlZ3JUSU6JRWK=
HuH-7 NH60S2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDWdG5mUUN3ME22PU4yODB{IN88US=> MnPyV2FPT0WU
NUGC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W5cWlEPTB;N{CuPVY1PCEQvF2= Ml;oV2FPT0WU
IST-SL1 M{LGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTdzLkKzNlQh|ryP MULTRW5ITVJ?
SHP-77 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD1TWM2OD15Mj6xNVkh|ryP M{\rR3NCVkeHUh?=
SW1116 M3WzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTd{LkG0NFch|ryP NGPURm9USU6JRWK=
LK-2 M1vK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7XcYFlUUN3ME23Nk45PjF{IN88US=> NFvyV2NUSU6JRWK=
U-2-OS M2\tNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3KfVJKSzVyPUezMlE5OjhizszN Mn\iV2FPT0WU
KYSE-150 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS4TWM2OD15Mz62NVE5KM7:TR?= NWTHSFFXW0GQR1XS
U251 NEjTS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrvTWM2OD15Mz64NVY5KM7:TR?= M3HoXXNCVkeHUh?=
HT-1080 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTd2LkK1O|Qh|ryP NYL5ZVFQW0GQR1XS
NCI-H1437 NWroUlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTd2Lk[zNlYh|ryP M{X0SXNCVkeHUh?=
HPAF-II MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nmdGlEPTB;N{SuOlQyPSEQvF2= NY\JcIw1W0GQR1XS
Becker MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTd3LkGxNFUh|ryP NEnRU4pUSU6JRWK=
PANC-10-05 M3Owbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi3[mlsUUN3ME23OU4zQDZ3IN88US=> MnqzV2FPT0WU
TYK-nu NY[5VplYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzhTWM2OD15NT6zNVAzKM7:TR?= NGDSOG1USU6JRWK=
SKG-IIIa M3XRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTd3LkOzOFEh|ryP Ml\QV2FPT0WU
NCI-H1993 NInZZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTd3LkezPVch|ryP M1;vdnNCVkeHUh?=
S-117 NI[xT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:2eGlEPTB;N{WuO|U2KM7:TR?= M4LN[XNCVkeHUh?=
HuO9 NHHKcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHFTWM2OD15Nj6wNFQ5KM7:TR?= M4TifHNCVkeHUh?=
CAL-51 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrVU5lRUUN3ME23Ok4yODB4IN88US=> MkKyV2FPT0WU
BT-20 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPwOFlKSzVyPUe2MlIyPjhizszN NV\NT4lKW0GQR1XS
LB831-BLC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:xeIRKSzVyPUe2MlMzOTdizszN MWnTRW5ITVJ?
LB1047-RCC NWewe5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnxTWM2OD15Nj63OlE6KM7:TR?= MVjTRW5ITVJ?
ES8 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32yUWlEPTB;N{iuNFA4OyEQvF2= M3;6OXNCVkeHUh?=
UMC-11 NXv0cmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[2TWM2OD15OD6wPFg1KM7:TR?= M2XwWXNCVkeHUh?=
NCI-H226 M4LMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fne2lEPTB;N{iuNVMyPSEQvF2= MWPTRW5ITVJ?
IGROV-1 NVXmUIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTd6LkW1OUDPxE1? MVnTRW5ITVJ?
BHY NEPlV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTd7LkW5OkDPxE1? MY\TRW5ITVJ?
MKN45 NYDTVZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[2W2FKSzVyPUiwMlMyPzRizszN MWDTRW5ITVJ?
IA-LM MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTFTWM2OD16MD6zOVEyKM7:TR?= NIPaXHBUSU6JRWK=
WM-115 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnme|dKSzVyPUixMlQyOTRizszN NWTVV|N7W0GQR1XS
VMRC-RCZ MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnuT3FKSzVyPUixMlQ1OjVizszN M1P6dHNCVkeHUh?=
NCI-H2291 NWfzWGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL4VJpDUUN3ME24NU43QDR{IN88US=> NVXVNo4zW0GQR1XS
MCF7 Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTh|LkK4PVch|ryP NULPOHcyW0GQR1XS
639-V M2P0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLzS5ZKSzVyPUi0MlYyOjlizszN M4XWNnNCVkeHUh?=
RT4 NX7QU2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHjeVVKSzVyPUi1MlI1ODNizszN NH[zbmNUSU6JRWK=
NCI-H2405 NVvwWG1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTh3LkK5PVch|ryP M4TpfHNCVkeHUh?=
CAL-33 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjrUlRKSzVyPUi1MlY{OTVizszN NF3aT|NUSU6JRWK=
BT-549 NUS3OY5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfmTWM2OD16NT65N|gzKM7:TR?= MWLTRW5ITVJ?
HT-1197 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL2VIExUUN3ME24PE4yODd5IN88US=> M{PqRXNCVkeHUh?=
G-361 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH5TWM2OD16OD6xOFc1KM7:TR?= NYPGcYozW0GQR1XS
LS-411N M324eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTh7LkOzPFgh|ryP NITrT3hUSU6JRWK=
HT-144 NXK1dIlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17BNGlEPTB;OEmuOVk6OiEQvF2= NVTHbmlkW0GQR1XS
DJM-1 M4PlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zUNGlEPTB;OEmuPFg1PSEQvF2= MWjTRW5ITVJ?
CAL-12T M{LmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGWWlEPTB;OUCuO|g6PSEQvF2= M1\tPHNCVkeHUh?=
MKN7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP4TWM2OD17MT6zOVUyKM7:TR?= MkDNV2FPT0WU
HuP-T3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzaTWM2OD17Nj6xNFA1KM7:TR?= M{X6SXNCVkeHUh?=
SK-MG-1 M3ToOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTJTWM2OD17Nj6xN|Q5KM7:TR?= MVvTRW5ITVJ?
NCI-H2347 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTl6LkGwOFIh|ryP MUHTRW5ITVJ?
SW872 M3y3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L4bWlEPTB;MUCwMlQ2PiEQvF2= M2TBVXNCVkeHUh?=
COLO-829 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFyMD61OVMh|ryP M3zMXXNCVkeHUh?=
MC-IXC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDrSmVWUUN3ME2xNFAvPjF3IN88US=> MlO3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A
Smiles CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C([NH]3)C=CC(=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID